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Abstract
Background
Nontyphoidal strains of Salmonella are a leading cause of death among HIV-infected Afri-
cans. Antibody-induced complement-mediated killing protects healthy Africans against Sal-
monella, but increased levels of anti-lipopolysaccharide (LPS) antibodies in some HIV-
infected African adults block this killing. The objective was to understand how these high
levels of anti-LPS antibodies interfere with the killing of Salmonella.
Methodology/Principal Findings
Sera and affinity-purified antibodies from African HIV-infected adults that failed to kill inva-
sive S. Typhimurium D23580 were compared to sera from HIV-uninfected and HIV-infected
subjects with bactericidal activity. The failure of sera from certain HIV-infected subjects to
kill Salmonella was found to be due to an inherent inhibitory effect of anti-LPS antibodies.
This inhibition was concentration-dependent and strongly associated with IgA and IgG2
anti-LPS antibodies (p<0.0001 for both). IgG anti-LPS antibodies, from sera of HIV-infected
individuals that inhibit killing at high concentration, induced killing when diluted. Conversely,
IgG, from sera of HIV-uninfected adults that induce killing, inhibited killing when concen-
trated. IgM anti-LPS antibodies from all subjects also induced Salmonella killing. Finally, the
inhibitory effect of high concentrations of anti-LPS antibodies is seen with IgM as well as
IgG and IgA. No correlation was found between affinity or avidity, or complement deposition
or consumption, and inhibition of killing.
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Conclusion/Significance
IgG and IgM classes of anti-S. Typhimurium LPS antibodies from HIV-infected and HIV-
uninfected individuals are bactericidal, while at very high concentrations, anti-LPS antibod-
ies of all classes inhibit in vitro killing of Salmonella. This could be due to a variety of mecha-
nisms relating to the poor ability of IgA and IgG2 to activate complement, and deposition of
complement at sites where it cannot insert in the bacterial membrane. Vaccine trials are
required to understand the significance of lack of in vitro killing by anti-LPS antibodies from
a minority of HIV-infected individuals with impaired immune homeostasis.
Author Summary
Bacteremia caused by nontyphoidal Salmonellae are a major health burden in Africa.
While antibody-induced complement-mediated killing protects healthy Africans against
Salmonella, increased levels of anti-LPS antibodies in some HIV-infected Africans block
this killing. Little is known about the mechanism of the interference of killing by these
antibodies. Here, we compared sera and affinity-purified antibodies from African HIV-
infected adults that are unable to kill invasive S. Typhimurium D23580, with sera from
HIV-uninfected and HIV-infected subjects with bactericidal activity. We found that the
blocking effect of anti-LPS antibodies is a factor of antibody concentration, rather than
antibody structure or specificity. While all three isotypes (IgG, IgA and IgM) can inhibit
killing of Salmonella at grossly high concentrations, the IgG and IgM isotypes of the anti-
LPS antibodies have in vitro bactericidal activity against invasive African S. Typhimurium.
Inhibition of killing did not associate with antibody affinity or avidity, or complement
deposition or consumption. It is possible that a LPS-based vaccine would induce antibod-
ies at bactericidal rather than inhibitory concentrations in HIV-uninfected individuals. In
HIV-infected individuals, it is uncertain whether vaccination will induce a protective
response or a dysregulated excess of anti-LPS antibodies that impairs serum killing of
Salmonella.
Introduction
African clades of nontyphoidal Salmonella (NTS), particularly S. enterica serovars Typhimur-
ium and Enteritidis, are a major cause of bacteremia in sub-Saharan Africa [1, 2]. Case fatality
rates are around 20–25% [1], and up to 47% in HIV-infected adults [3] prior to the availability
of antiretroviral therapy. Diagnosing NTS bacteremia is difficult due to a lack of specific clini-
cal presentation. The emergence of multi-drug resistant isolates [4] has added to the problem
of management and no vaccine is currently available. NTS bacteremia in Africa occurs most
frequently among infants and HIV-infected patients [1, 2]. The underlying mechanisms of sus-
ceptibility are not fully understood. We have previously shown that sera from African children
under two years of age lack Salmonella-specific antibodies, resulting in an impaired ability to
kill Salmonella. Sera from adults with Salmonella-specific antibodies can induce complement-
mediated killing of Salmonella and placental transfer of IgG offers protection to infants [5],
suggesting a role for antibody in protection against invasive NTS (iNTS) disease.
Mice can be protected against an intraperitoneal challenge with S. Typhimurium either by
immunization with experimental LPS O-antigen-based conjugate vaccines [6, 7] or passive
transfer of monoclonal antibodies against O-antigens [8, 9]. The role of anti-LPS antibodies in
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protection against iNTS disease in man is not fully appreciated, although antibodies to S.
Typhimurium LPS O-antigen correlate with serum killing of S. Typhimurium D23580 in Mala-
wian children [10].
Immunity against iNTS in HIV-infected adults is complex. Our work in Malawi demon-
strates an association between impaired serum killing of NTS and dysregulated production of
high levels of antibodies to S. Typhimurium LPS in some HIV-infected African adults [11].
Removal of LPS-specific antibodies restores bactericidal activity. In this study, we investigate
the mechanism of interference with killing of NTS by antibodies to LPS O-antigen in HIV-
infected African adults. This is important for understanding the potential effectiveness of an
NTS O-antigen-based vaccine in Africa, particularly in the context of HIV infection.
Methods
Sera
Sera were from HIV-infected and HIV-uninfected Malawian adults (S1 Table) and were the
same as previously studied [11]. No individuals had a known clinical history of iNTS disease.
The study was approved by the College of Medical Research and Ethics Committee, College of
Medicine, University of Malawi. Written informed consent was obtained from participants
prior to inclusion in the study.
Bacteria
Invasive African S. Typhimurium D23580 belonging to the ST313 pathovar [5, 12], D23580
galE-, S. Typhimurium LT2 [13], S. Enteritidis D24854, S. Enteritidis SL7488 [14], S. Senften-
berg 20050439 and S. Agona 20071186 [15] were used.
Anti-Salmonella antibody binding
This was as described previously [5]. Briefly, bacteria were mixed with 10% serum (final Salmo-
nella concentration 2 × 108 CFU/ml). After washing, bound antibodies were detected with
FITC-conjugated anti-human IgG, IgA, and IgM antibodies (Sigma-Aldrich, Milan, Italy). FL1
channel fluorescence indicates anti-Salmonella antibody binding.
Anti-LPS ELISA
S. Typhimurium LPS (Alexis Biochemicals, Vinci, Italy) was coated onto ELISA plates at 5 μg/
ml and dilutions of serum sample [10] added. Anti-LPS antibodies were detected using alka-
line-phosphatase-conjugated anti-human isotype-specific antibodies (Southern Biotech,
Milan, Italy).
Serum bactericidal assays
These were as previously described [11, 16]. For SBA involving endogenous complement, bac-
teria in log-growth phase were added to undiluted serum (final Salmonella concentration 106
CFU/ml) and incubated at 37°C. Viable Salmonellae were determined after 180 min. For SBA
involving exogenous complement, bacteria were added to a mixture of heat-inactivated test
serum (56°C for 30 minutes) and 75% baby rabbit serum (BRS, AbD Serotec, Kidlington, UK).
For SBA testing inhibition of serum bactericidal activity, bacteria were added to a mixture of
the purified antibodies and 50% normal human adult serum. Non-Salmonella-specific isotype-
matched control antibodies were purified paraproteins.
HIV and Immunity to Salmonella
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Affinity-purification of isotype-specific total antibodies
To obtain total antibody of each isotype (IgG, IgA, IgM), serum was incubated sequentially
with combinations of human IgA and IgM affinity matrices (CaptureSelect, Leiden, Nether-
lands) and protein G affinity matrix (GE Healthcare) to remove IgA, IgM and IgG respectively.
Resulting isotype-specific antibodies preparations were dialyzed against PBS.
Extraction of anti-Salmonella LPS isotypes
Anti-Salmonella LPS antibodies were extracted from affinity-purified total IgG, IgA and IgM
using a S. Typhimurium D23580 LPS O-antigen column, as described previously [17]. Anti-
LPS antibodies were eluted with 0.1 M glycine pH 3 and neutralized with 1 M Tris-HCl pH 8.0.
Extracted antibodies were dialyzed against PBS.
kd analysis
Binding of serum antibodies to S. Typhimurium LPS were assessed using a Biacore 3000 system
(GE Healthcare). A hydrophobic HPA sensor chip was coated by passing 1 mg/ml LPS across
the chip surface for 30 min at 2 μl/min, washed with 0.1 M hydrochloride acid and blocked
with 0.1 mg/ml bovine serum albumin. Sera were diluted 1:2 and passed across the chip surface
for 10 min at 5 μl/min. kd values were calculated by fitting the binding curves to a best-fit Lang-
muir 1:1 model using BiaEvaluation.
Affinity of anti-Salmonella LPS antibodies
ELISA plates were coated with S. Typhimurium LPS at either a non-limiting concentration of
5 μg/ml or limiting concentration of 0.5 μg/ml. Diluted human sera were added to both plate
types and incubated with alkaline-phosphatase-conjugated anti-human IgG, IgA or IgM
(Southern Biotech), then SigmaFast. Affinity was calculated as the ratio of the antibody titer
with limiting plates to titer with non-limiting plates [18].
Avidity of anti-Salmonella LPS antibodies
Plates were coated with S. Typhimurium LPS at 5 μg/ml and diluted human serum added. Half
the wells were washed with 6 M urea and half with PBS-0.05% Tween 20, then incubated with
secondary antibodies followed by SigmaFast, as above. The avidity index is the antibody titer in
the presence of urea as a percentage of titer in the absence of urea [19].
Absolute quantification of anti-S. Typhimurium LPS antibody
concentrations
Anti-S. Typhimurium LPS antibody concentrations were determined by ELISA using control
antibodies of known concentration. Plates were coated with goat anti-human IgA, IgG or IgM
antibodies (Sigma-Aldrich) at 5 μg/ml. Purified anti-LPS antibody eluates, together with the
control antibodies, were added in step-wise dilutions. Bound antibodies were detected using
secondary antibodies, then SigmaFast, as above.
C3/C5b-9 complement deposition assays
These were by flow cytometry as previously described [5]. Bacteria in log-growth phase were
mixed with undiluted serum (final concentration 2 × 108 CFU/ml), then FITC-conjugated
mouse anti-C3 antibody or mouse anti-C5b-9 antibody followed by FITC-conjugated anti-
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mouse immunoglobulin. The bacteria were first gated on FSC and SSC to exclude bacterial cell
debris. GMFI in the FL1 channel was used to indicate C3 and C5b-9 deposition.
Functional complement assays
Total complement activity and alternative hemolytic complement activity were measured by
radial immunodiffusion assays according to manufacturer’s instructions (Binding Site, Grasso-
bio, Italy).
Statistical methods
Spearman rank was used for estimation of correlation. Comparisons of data from different
groups of sera were performed by Mann-Whitney U-test.
Results
Anti-LPS isotypes from HIV-infected adults that induce or inhibit S.
Typhimurium killing
We previously reported that ability of serum from HIV-infected Africans to induce comple-
ment-mediated killing of S. Typhimurium correlates inversely with concentration of anti-LPS
antibody [11]. When S. Typhimurium D23580 is cultured with serum from HIV-uninfected
healthy adults, the number of viable bacteria falls to between 10% and 1% of the starting value
after 180 minutes. By contrast, sera from HIV-infected adults with high anti-LPS titers fail to
kill D23580.
Our first objective was to test whether anti-LPS antibodies of a particular class or subclass
fail to induce killing of S. Typhimurium D23580 and act as a competitive inhibitor of antibod-
ies that induce killing. As a preliminary, we assessed which serum immunoglobulin classes and
subclasses are represented among anti-LPS antibodies found in HIV-uninfected and HIV-
infected African adults. The ability of each individual serum to kill S. Typhimurium D23580
compared to IgG, IgM, IgA, IgG1 and IgG2 anti-LPS concentration of that serum is shown in
Fig 1. There is a trend towards negative correlation between serum killing capacity and anti-
LPS levels of each antibody isotype that only fails to reach statistical significance for IgM (Fig
1). The strongest negative correlation is shown for IgA and IgG2, the antibody classes that are
least able to fix complement and consequently the strongest candidates as competitive inhibi-
tors of Salmonella killing.
For more direct evidence about the capacity of different anti-LPS antibody classes to kill S.
Typhimurium, total IgA, IgG and IgM were prepared from serum of three HIV-uninfected
subjects (‘HIV-ve bactericidal’ serum), four HIV-infected subjects that effect normal killing of
S. Typhimurium (‘HIV+ve bactericidal’ serum), and five HIV-infected subjects whose serum
does not kill (‘HIV+ve inhibitory’ serum). Purified total IgG, IgM and IgA from each of these
12 sera were tested in a modified SBA with S. Typhimurium D23580 and dilutions of affinity
purified immunoglobulin and 75% baby rabbit serum (BRS) as the source of complement [16]
(Fig 2). Purified total IgG (top panel) from HIV-ve bactericidal sera and HIV+ve inhibitory
sera were bactericidal against S. Typhimurium D23580 in the presence of BRS. Importantly,
there is no loss of killing at 500μg/ml with all eight sera in these two groups, indicating that
even high concentrations of these IgG preparations are not anti-complementary. Strikingly,
none of the total IgG purified from HIV+ve bactericidal sera induced killing at any concentra-
tion tested. The highest IgG concentration tested (500 μg/ml) was below normal physiological
levels in blood (6–16 mg/ml).
HIV and Immunity to Salmonella
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Fig 1. Association of impaired serum killing of S. Typhimuriumwith anti-LPS IgG, IgM, IgA, IgG1 and
IgG2. Log growth phase S. Typhimurium D23580 was added to whole serum and the log10 proportion of the
starting number of bacteria remaining after 180 minutes was determined on LB agar. Each panel indicates
the proportion of bacteria recovered after 180 minutes in serum from HIV-uninfected subjects (n = 58, left)
and HIV-infected subjects (n = 58, right) plotted against the anti-LPS concentration of that serum. Dashed line
indicates threshold for impaired killing. Anti-LPS antibody concentration of the sera were determined using
HIV and Immunity to Salmonella
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The killing observed in whole serum from many HIV-infected subjects may be primarily be
due to IgM anti-LPS, since purified IgM HIV+ve bactericidal serum killed S. Typhimurium in
the presence of BRS (Fig 2, central panel). Total IgM from HIV+ve inhibitory serum was also
anti-LPS ELISA, with S. Typhimurium LPS coated onto ELISA plates at 5 μg/ml. Anti-LPS antibodies were
detected using alkaline-phosphatase-conjugated anti-human isotype-specific antibodies. Each point
represents one serum. r, Spearman’s correlation coefficient.
doi:10.1371/journal.pntd.0004604.g001
Fig 2. Killing of S. Typhimurium by total IgG, IgM and IgA from HIV-uninfected and HIV-infected sera. Log growth phase S. Typhimurium D23580 was
added to a mixture of the purified antibodies and 75% BRS. The log10 proportion of the starting number of bacteria remaining after 180 minutes was
determined on LB agar. To obtain total antibody of each isotype (IgG, IgM and IgA), serum was incubated sequentially with combinations of human IgA and
IgM affinity matrices and protein G affinity matrix to remove IgA, IgM and IgG respectively. Sera used were HIV-uninfected (HIV-ve bactericidal, n = 3), HIV-
infected bactericidal (HIV+ve bactericidal, n = 4) and HIV-infected inhibitory (HIV+ve inhibitory, n = 5) sera. Each line represents killing by purified total IgG,
IgM or IgA antibodies from one serum. Data shown are from a single representative experiment, where each of the three independent experiments was
performed in technical triplicates.
doi:10.1371/journal.pntd.0004604.g002
HIV and Immunity to Salmonella
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bactericidal, as was total IgM from HIV-ve bactericidal serum. All of these total IgM prepara-
tions induced somewhat less killing at the highest concentration tested (500 μg/ml) than at a
five-fold lower concentration. None of the total IgA preparations from any of the three groups
induced killing of S. Typhimurium D23580 at any concentration tested (Fig 2, bottom row).
This is consistent with IgA not activating antibody-dependent classical complement pathway
[18]. It also suggests that anti-LPS IgA in high concentration can act as a competitive inhibitor
of antibody-induced complement-mediated killing of S. Typhimurium.
To relate these findings to S. Typhimurium LPS-specific antibodies, we affinity purified
anti-LPS antibodies from each total immunoglobulin preparation and repeated the modified
SBA. Remarkably, the results with anti-LPS antibodies of each class almost completely mir-
rored those with total immunoglobulins of each class, consistent with anti-LPS antibodies in
each serum effecting the killing observed (Fig 3). The relative lack of bactericidal activity of
anti-LPS IgG from HIV+ve bactericidal sera total IgG was again surprising. We speculated
whether differences in the fine specificities of the S. Typhimurium O-antigen epitopes recog-
nized by these IgG antibodies could be responsible. Since anti-LPS antibodies were affinity-
purified using O-antigen from S. Typhimurium D23580 (consisting of O:1, O:4, O:5 and O:12
epitopes), anti-LPS IgG from HIV+ve bactericidal sera potentially could target a different bal-
ance of O-antigen epitopes compared with anti-LPS IgG from the other sera groups. To test
this, we examined the ability of purified anti-LPS IgG from HIV+ve bactericidal sera to kill Sal-
monella with different O-antigen profiles (S2 Table, Fig 4A–4F).
As well as being unable to kill S. Typhimurium D23580, anti-LPS IgG from HIV+ve bacteri-
cidal sera exhibited weak bactericidal activity against S. Typhimurium LT2 (both O:1, O:4, O:5,
O:12), possibly due to the higher serum sensitivity of LT2 compared with D23580 [16]. These
IgG antibodies could not kill S. Enteritidis D24954 (O:1, O:9, O:12), but could kill S. Senften-
berg (O:1, O:3, O:19). As O:1 antigen is the only O-antigen common between S. Senftenberg
and S. Typhimurium D23580 (used to purify the anti-LPS antibodies), killing of S. Senftenberg
was most likely mediated by antibodies to O:1 antigen, an α(1!6) glucosylated galactose
found on the LPS backbone [9,19]. Absence of bactericidal activity with S. Typhimurium
D23580 and S. Enteritidis D24954, which also express O:1, could be due to differences in O-
antigen chain length, and glucosylation and O-acetylation levels which impact on the tridimen-
sional structure of these side chains, reducing accessibility of IgG antibodies to the O:1 antigen.
Anti-LPS IgG from HIV+ve bactericidal sera killed S. Enteritidis SL7488 (O:1, O:4, O:12) and
S. Agona (O:4, O:12), likely due to antibodies to O:4 antigen which is present on both strains,
but is less accessible to antibody in the presence of the O:5 antigen of S. Typhimurium D23580
and LT2. Analysis of the anti-LPS IgG from the HIV+ve bactericidal sera by flow cytometry
(Fig 4G) showed higher binding to S. Enteritidis SL7488 and S. Agona compared to the other
bacterial strains. This is consistent with antibody binding to the exposed O:4 epitope on these
two strains.
Inhibition of killing of S. Typhimurium by LPS-specific isotypes from sera
of HIV-infected adults
To test the possibility that specific IgA acts as a competitive inhibitor of antibody-induced kill-
ing of S. Typhimurium D23580, we added purified anti-LPS antibodies from each of the total
IgG, IgM and IgA preparations to SBA of S. Typhimurium D23580 with 50% HIV-ve bacteri-
cidal adult African serum as a source of both anti-Salmonella antibodies, that induce killing,
and complement (Fig 5). Perhaps surprisingly, 500 μg/ml anti-LPS of each of the three immu-
noglobulin classes from the sera of all three groups inhibited antibody-induced complement-
mediated killing of S. Typhimurium D23580. This inhibition was lost after a four-fold dilution
HIV and Immunity to Salmonella
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of the anti-LPS IgA and IgG, and after one further dilution with anti-LPS IgM. As a control,
purified non-Salmonella specific human antibody preparations were added to the SBA and
failed to inhibit serum killing at 500 μg/ml.
Complement integrity in sera with high anti-LPS concentrations that
inhibit S. Typhimurium killing
The finding that high concentrations of anti-LPS antibody of all isotypes from each clinical
group inhibits complement-induced killing, prompted us to explore three possible mechanisms
for this effect. First, we tested whether HIV+ve inhibitory sera consume complement. Second,
Fig 3. Killing of S. Typhimurium by anti-LPS isotypes from HIV-ve bactericidal, HIV+ve bactericidal and HIV+ve inhibitory sera. Log growth phase S.
Typhimurium D23580 was added to a mixture of the purified antibodies and 75% BRS as complement source. The log10 proportion of the starting number of
bacteria remaining after 180 minutes was determined on LB agar. Anti-Salmonella LPS antibodies were extracted from affinity-purified total IgG, IgA and IgM
using a S. Typhimurium D23580 LPS O-antigen column. Each line represents killing by purified anti-LPS antibodies from one serum. Data shown are from a
single representative experiment, where each of the three independent experiments was performed in technical triplicates.
doi:10.1371/journal.pntd.0004604.g003
HIV and Immunity to Salmonella
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we investigated whether concentrations of anti-LPS antibodies that saturate O-antigen epitopes
on S. Typhimurium prevent formation of membrane attack complex (MAC) of complement.
Third, we checked whether MAC is formed, but prevented from inserting in the bacterial cell
wall in a damaging way by saturating concentrations of anti-LPS antibody.
To test for complement depletion in sera, SBA against S. Typhimurium D23580 were first
set up with the different sera. After 180 mins, the sera were sterile-filtered and complement
function assessed. All post-SBA filtrates could deposit C3 complement on S. Typhimurium as
assessed by flow cytometry. Most of the filtrates, including 5 of 6 from the HIV+ve inhibitory
group, also deposited MAC. There was no relative impairment of complement deposition with
HIV+ve inhibitory filtrates compared with those of the other two groups (Fig 6A and 6B). All
Fig 4. Killing of six strains of Salmonella by anti-LPS IgG from HIV+ve bactericidal sera. A) S. Typhimurium D23580, (B) S. Typhimurium LT2, (C) S.
Enteritidis D24954, (D) S. Senftenberg 20050439, (E) S. Enteritidis SL7488, (F) S. Agona 20071186. Log growth phase Salmonellawas added to a mixture of
the purified antibodies and 75% BRS as complement source. The log10 proportion of the starting number of bacteria remaining after 180 minutes was
determined on LB agar. (G) Flow cytometric determination of anti-LPS IgG, from HIV+ve bactericidal sera, to the Salmonella strains. Each line/point
represents one serum (n = 4).
doi:10.1371/journal.pntd.0004604.g004
HIV and Immunity to Salmonella
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post-SBA filtrates retained total and alternative pathway hemolytic complement activity (Fig
6C and 6D), although there was a trend for lower activity in the HIV+ve inhibitory filtrates
compared with the HIV-ve bactericidal filtrates. We previously demonstrated that 20% human
complement can effect bactericidal activity against S. Typhimurium D23580 in the presence of
specific antibodies [5]. Finally, post-SBA filtrates were tested for killing capacity in a second
SBA with S. Typhimurium D23580 galE-. This strain is sensitive to complement-mediated kill-
ing in the absence of antibodies [11]. All filtrates in each group, including the HIV+ve inhibi-
tory group, effected maximal killing of S. Typhimurium D23580 galE- after 45 minutes. Heat-
inactivation at 56°C for 30 minutes destroyed the lytic capacity of the filtrates (Fig 6E and 6F).
Fig 5. Inhibition of S. Typhimurium killing by anti-LPS antibodies from HIV-ve bactericidal, HIV+ve bactericidal and HIV+ve inhibitory sera. Log
growth phase S. Typhimurium D23580 was added to a mixture of the purified anti-LPS antibodies (from HIV-ve bactericidal, HIV+ve bactericidal and HIV+ve
inhibitory sera) and 50%HIV-uninfected human serum. The log10 proportion of the starting number of bacteria remaining after 180 minutes was determined
on LB agar. Each line represents inhibition of killing by anti-LPS antibodies from one serum. Data shown are from a single representative experiment, where
each of the three independent experiments was performed in technical triplicates.
doi:10.1371/journal.pntd.0004604.g005
HIV and Immunity to Salmonella
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Fig 6. Complement integrity of HIV-ve bactericidal, HIV+ve bactericidal and HIV+ve inhibitory sera following SBAwith S. Typhimurium. Log growth
phase S. Typhimurium D23580 was added to whole serum and incubated for 180 min in a SBA. Following the SBA, sera were filter-sterilized and examined
HIV and Immunity to Salmonella
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Anti-LPS-associated impaired Salmonella killing is not due to low
antibody affinity or avidity
We speculated that differences in affinity and avidity of antibodies targeting S. Typhimurium
LPS might contribute to the lack of serum bactericidal activity. Using Biacore, we determined
the dissociation constant (kd) of anti-S. Typhimurium D23580 LPS antibodies (Fig 7A) in each
group of sera (antibody titers shown in Fig 8 and S3 Table). The kd of anti-LPS antibodies in
HIV+ve inhibitory (P = 0.004) and HIV+ve bactericidal sera (P = 0.016) were lower than for
HIV-ve bactericidal sera. However there were no differences, as measured by ELISA, in affinity
(Fig 7B) and avidity (Fig 7C) of anti-LPS IgA, IgG and IgM between the three groups.
Discussion
S. Typhimurium LPS O-antigen has been considered as a vaccine candidate for many years.
We previously reported an association between impaired serum killing of S. Typhimurium and
high levels of S. Typhimurium LPS-specific IgG in some African HIV-infected adults [11]. This
study extends the association to high titers of anti-LPS IgA, but not IgM. Factors we examined
that do not appear to cause impaired killing are antibody affinity, avidity and complement con-
sumption. The latter was previously postulated as an explanation [11].
The first key finding is that antibody concentration is an important determinant of the pres-
ence or absence of serum killing of Salmonella. HIV+ve inhibitory sera have elevated LPS-spe-
cific IgA and IgG, compared with HIV-ve and HIV+ve bactericidal sera. While whole
undiluted HIV+ve inhibitory sera cannot kill S. Typhimurium D23580, these sera kill Salmo-
nella in the presence of exogenous complement when diluted. The concentration dependency
of killing is also observed with purified antibodies from all groups of sera. Killing is also iso-
type-dependent, being mediated by IgG and IgM in HIV-ve bactericidal sera, but predomi-
nantly by IgM in the HIV+ve bactericidal sera tested.
The counter-intuitive lack of killing observed with purified total and LPS-specific IgG from
HIV+ve bactericidal sera could be due to the epitopes recognized by these antibodies, suggest-
ing that the specific O-antigen epitopes recognized are important for efficient killing of Salmo-
nella. The SBA and flow cytometry experiments with Salmonella strains of different O-antigen
profiles supports this hypothesis and offers a possible explanation whereby preferential target-
ing of anti-LPS IgG from the HIV+ve bactericidal group to O:4 could underlie this finding.
The O:5 antigen, present in S. Typhimurium D23580, is an acetylated form of the O:4 antigen
[6, 20], and can hinder accessibility of antibodies targeting O:4. The underlying reasons for this
difference in epitope specificity of IgG anti-LPS antigens in HIV+ve bactericidal and HIV+ve
inhibitory sera are not clear. The difference may be partly explained by the small number of
sera available for antibody extraction. With larger numbers of sera, it is conceivable that both
bactericidal and inhibitory sera would be found with antibodies preferentially targeting the O:4
or O:5 epitopes. The presence of a skewing in antibody response to particularly epitopes is con-
sistent with the well-recognized B cell dysregulation and dysfunction observed in HIV infection
[21, 22], characterized by various abnormalities including oligoclonal antibody responses [23].
The second key finding is that anti-LPS antibodies from HIV-infected and HIV-uninfected
African adults can effect complement-dependent killing, indicating their potential for mediat-
ing protective immunity against NTS. Purified anti-LPS IgG and IgM kill Salmonella, while
for complement integrity. (A) C3 and (B) MAC deposition on D23580 detected by flow cytometry using anti-C3 and anti-MAC (anti-C5b-9) antibodies followed
by FITC-conjugated anti-mouse immunoglobulin. (C) Total hemolytic and (D) alternative complement activity measured by radial immunodiffusion assay.
Bactericidal potential at 45 min in a new whole serum SBA with galE- D23580 using (E) fresh and (F) heat-inactivated filtrates. Data shown are from a single
representative experiment, where each of the three independent experiments was performed in technical triplicates.
doi:10.1371/journal.pntd.0004604.g006
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IgA does not. Hence, bactericidal activity is dependent on antibody isotype, which is consistent
with the known ability of IgM, IgG1 and IgG3, but not IgA, and only to a limited extent IgG2,
to activate complement [24–26]. While purified IgA from African adults could not effect
Fig 7. kd, affinity and avidity of anti-LPS antibodies from HIV-infected and HIV-uninfected adults. (A) kd values for total anti-LPS antibodies in HIV-ve
bactericidal, HIV+ve bactericidal, HIV+ve inhibitory sera. Binding of serum antibodies to S. Typhimurium LPS were assessed using a Biacore 3000 system. A
hydrophobic HPA sensor chip was coated by passing LPS across the chip surface, washed with hydrochloride acid and blocked with bovine serum albumin.
Sera were diluted 1:2 and passed across the chip surface. kd values were calculated by fitting the binding curves to a best-fit Langmuir 1:1 model using
BiaEvaluation. (B) Affinity and (C) avidity of isotype-specific anti-LPS antibodies, as measured by ELISA. IgG4 was not detected. For affinity measurement,
ELISA plates were coated with S. Typhimurium LPS at either a non-limiting concentration of 5 μg/ml or limiting concentration of 0.5 μg/ml. Affinity was
calculated as the ratio of the antibody titer with limiting plates to titer with non-limiting plates. For avidity measurement, ELISA plates were coated with S.
Typhimurium LPS at 5 μg/ml and ELISA was performed using diluted human serum. For this ELISA, half the wells were washed with 6 M urea and half with
PBS-0.05% Tween 20. The avidity index is antibody titer in the presence of urea as a percentage of titer in the absence of urea. Comparison between groups
by Mann-Whitney U-test.
doi:10.1371/journal.pntd.0004604.g007
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complement-mediated killing of Salmonella, we recently found that a vaccine-induced mouse
monoclonal IgA against O:4 of S. Typhimurium LPS has bactericidal activity [8]. This could
simply be due to species differences between human and mouse IgA. While serum IgA did not
kill Salmonella, secretory IgA, which was not examined in this study, is likely to be important
for reducing Salmonella colonization via the oral route.
Concentration of anti-LPS IgA and IgG2 in total serum from HIV-infected participants cor-
related most strongly with inhibition of Salmonella killing (P<0.0001 for both) and it is possi-
ble that the high levels of this immunoglobulin class and subclass in HIV+ve inhibitory serum
contributes to impaired killing. Very few HIV-uninfected participants had raised IgG2 levels in
comparison with HIV-infected participants. Although IgG1 is the most abundant IgG subclass
in human serum, IgG2 appears to be induced preferentially to bacterial polysaccharides [27].
As well as its poor ability to activate complement, high levels of IgG2 to Pseudomonas aerugi-
nosa LPS in patients with bronchiectasis have been found recently to inhibit serum killing of
these bacteria [28].
The relevance of different antibody isotypes for protection has implications for vaccine
development against invasive Salmonella disease. Vaccine design, formulation and regimes
that induce antibody responses consisting predominantly of IgG1 and IgM are more likely to
elicit bactericidal antibodies which can counter bacteremia, while IgA induction is likely to be
important for preventing the initial invasion from the gastrointestinal tract.
Fig 8. Total anti-S. Typhimurium and specific anti-S. Typhimurium LPS antibody in sera from HIV-infected and HIV-uninfected adults. (A) Total anti-
S. Typhimurium antibody levels in the different groups of sera (HIV-ve bactericidal, HIV+ve bactericidal and HIV+ve inhibitory) by flow cytometry. (B) Specific
anti-S. Typhimurium LPS antibody levels by ELISA. Anti-LPS antibody concentration of the sera were determined using anti-LPS ELISA, where S.
Typhimurium LPS was coated onto ELISA plates at 5 μg/ml. Anti-LPS antibodies were detected using alkaline-phosphatase-conjugated anti-human isotype-
specific antibodies. Each point represents one serum.
doi:10.1371/journal.pntd.0004604.g008
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The third key finding is that while anti-LPS IgG and IgM are bactericidal at low concentra-
tions, high concentrations inhibit normal serum killing. Together, these findings suggest that
impaired killing with HIV+ve inhibitory sera is primarily the outcome of high anti-LPS anti-
bodies concentrations. The exact mechanism by which this inhibition occurs is still unclear,
but could partly be due to the very high levels of anti-LPS IgA and IgG2 antibodies in HIV+ve
inhibitory sera which are non/poorly-complement activating. This does not, however, appear
to explain the similar profiles of killing and lack of killing by anti-LPS antibodies extracted
from HIV-infected and HIV-uninfected sera over the range of concentrations tested, with the
possible exception of lack of killing of IgG with HIV+ve bactericidal sera if this was predomi-
nantly IgG2 subclass.
As previously postulated [11], binding of an excess of antibodies to the Salmonella surface
could sterically hinder insertion of the MAC into the bacterial membrane, so that although
MAC is formed, as we have detected, it is unable to kill Salmonella. Lack of killing could also
result from deposition of MAC at a distance away from the bacterial surface, since anti-LPS
antibodies will bind theoretically along the length of the LPS molecule, with some locations dis-
tal to the bacterial surface. Location of MAC deposition has previously been highlighted as an
important factor in killing of Salmonella Typhimurium [29]. However, this alone cannot be the
full explanation, since anti-LPS antibodies are bactericidal [7, 8, 30], unless distal MAC deposi-
tion occurs preferentially at higher anti-LPS antibody concentrations. Such distally-positioned
MACmay be prone to shedding from the bacteria as previously demonstrated for S. Minnesota
[31, 32]. Finally, it is conceivable that high concentrations of antibodies bound to individual
bacteria may result in defective formation of the MAC, leading to a lack of killing.
Trebicka et al. have recently described the absence of killing of S. Typhimurium by sera
from HIV-infected Americans associated with a lack of IgG antibodies to LPS [33], rather than
the high levels of these antibodies that we have found in HIV-infected Africans. This is consis-
tent with the concept that some, but not excessive, antibodies to LPS are required to kill Salmo-
nella. The reason for the absence of antibodies to LPS may relate to differences in exposure to
Salmonella in the USA compared with Africa, leading to reduced antigenic stimulation of LPS-
specific B cells, or to differences in the nature of B cell dysfunction and dysregulation between
the two study populations. Interestingly, despite the lack of anti-LPS antibodies, Trebicka et al
found that these HIV-infected sera inhibited killing of Salmonella by control sera, suggesting
multiple mechanisms for impairment of killing of Salmonella in HIV infection. Although data
on levels of IgA and IgM antibodies to LPS were not shown, the authors speculated that high
levels anti-LPS IgM present in some study participants could be the reason for inhibition of
killing. This is consistent with the findings in our current study.
The LPS-specific hypergammaglobulinemia found in some HIV-infected African adults is
not present in HIV-uninfected subjects, and appears to occur secondary to natural exposure to
S. Typhimurium in the context of the dysregulated humoral immunity that accompanies HIV
infection [11]. Inhibition of normal serum killing of Salmonella by anti-LPS IgG and IgM
required 500 μg/ml and 125 μg/ml purified antibodies respectively. The combined concentra-
tions of all anti-LPS antibody isotypes exceeded 500 μg/ml in HIV+ve inhibitory sera, but were
below 500 μg/ml in HIV+ve and HIV-ve bactericidal sera. Immunization has been reported to
induce*15 μg/ml specific IgG in healthy adults [34, 35]. Therefore, a S. Typhimurium O-anti-
gen-based vaccine should induce antibodies at bactericidal rather than inhibitory concentra-
tions in HIV-uninfected individuals.
Several factors could determine the immunological response to such a vaccine in HIV-
infected individuals. HIV infection has a global effect on the immune system characterized by
impaired immune homeostasis, and is associated with higher risk and increased severity of
infections including pneumonia and tuberculosis [36, 37]. The difference in immunity
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resulting from vaccination instead of natural exposure to NTS is uncertain, as is the effect anti-
retroviral therapy will have on anti-Salmonella LPS antibody levels. Therefore, it is not known
whether vaccination will induce a protective response or a dysregulated excess of anti-LPS anti-
bodies that impairs serum Salmonella killing.
In conclusion, antibodies against S. Typhimurium LPS O-antigen are present in the blood
of HIV-infected and HIV-uninfected African adults, most likely following natural exposure to
S. Typhimurium. The IgG and IgM isotypes of these antibodies have in vitro bactericidal activ-
ity against invasive African S. Typhimurium, but at high concentrations, all three isotypes
(IgG, IgA and IgM) can inhibit killing of Salmonella.
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